NCT04321525

Brief Summary

Cognitive Behavioral Therapy (CBT) is the most prestigious psychological treatment for depression. However, not only do we need to increase its efficacy but also to widen the repertoire of evidence-based psychotherapeutic interventions. The importance of the patient's engagement in treatment is highlighted in the literature as a key factor for a good therapeutic outcome over and above the type of therapy. In this sense, personal construct therapy (PCT), with some promising supporting evidence, is particularly suited to fit the personal values and attitudes of each patient. In contrast to CBT, PCT does not educate patients about depression and give them directions on the changes to be made in their dysfunctional behaviors or cognitions. Rather, PCT explores their coherence with respect to the person's sense of identity, their construction of self and others, and works with the conflicts or dilemmas that appear during this conjoint exploration using the Repertory Grid Technique (RGT). In this project, for the first time, the RGT will be implemented using Virtual Reality (VR). This format could be highly appealing for young people, thus facilitating their involvement in therapy. The efficacy of this innovative application of PCT using VR (PCT-VR) will be compared to usual PCT, and to CBT in a randomized clinical trial. The Beck Depression Inventory-II is the primary outcome measure for calculating both statistical and clinical significance, but other measures will also be used at pre-, post-therapy and six-month follow up. The trial will be done in a natural health context, mostly the usual primary care center of each patient, with those who consult during the active period of the study. Our research group has been working on both depression and personal construct theory for more than two decades (this includes our previous funded projects), particularly with a dilemma-focused intervention aimed to resolve the cognitive conflicts detected with the RGT. By fostering a technological innovation with VR, it is expected to boost the current efficacy of psychotherapy by increasing the engagement of young people and obtaining better outcomes. If these goals are met, a pathological evolution of the patient with its associated personal, health and social costs could be avoided.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable depression

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable depression

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 18, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 25, 2020

Completed
1.6 years until next milestone

Study Start

First participant enrolled

October 15, 2021

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2024

Completed
Last Updated

December 9, 2024

Status Verified

December 1, 2024

Enrollment Period

1.8 years

First QC Date

February 18, 2020

Last Update Submit

December 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Beck depression inventory second edition

    Beck Depression Inventory, Second Edition (BDI-II; Beck, Steer \& Brown, 1996). It is a 21-item self-report instrument to assess the existence and severity of symptoms of depression. Both the original and the Spanish version (Sanz, Perdigón, \& Vázquez, 2003) showed good psychometric properties and acceptability.

    BDI-II is administered at the end of therapy (10 weeks), and 6-month follow-up

Secondary Outcomes (4)

  • Clinical Outcomes in Routine Evaluation-Outcome Measure

    CORE-OM is administered at baseline, and then routinely every session (using short forms versions A and B) until the end of treatment (10 weeks), and 6-month follow-up

  • - Depression, Anxiety and Stress Scales

    DASS-21 is administered at the end of therapy (10 weeks), and 6-month follow-up

  • Session Rating Scale 3.0

    SRS 3.0 is administered routinely after every session, through intervention completion (10 weeks), and 6-month follow-up

  • Change Interview

    administered at the end of therapy (10 weeks)

Other Outcomes (2)

  • Treatment adherence scale

    Administered at the end of therapy (up to 1 year)

  • Consumer Reports Effectiveness Scale

    administered at the end of therapy (10 weeks)

Study Arms (3)

Cognitive-behavioral therapy (CBT)

ACTIVE COMPARATOR

Individual Cognitive Behavioral Therapy

Behavioral: Cognitive-behavioral therapy

Personal construct therapy (PCT)

EXPERIMENTAL

Individual Personal Construct Therapy

Behavioral: Personal Construct Therapy

Personal construct therapy with virtual reality (PCT-VR)

EXPERIMENTAL

Individual Personal Construct Therapy with an immersive virtual reality app

Behavioral: Personal Construct Therapy with virtual reality

Interventions

10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session

Also known as: Cognitive therapy
Cognitive-behavioral therapy (CBT)

10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session

Personal construct therapy (PCT)

10 individual one-hour sessions, with one or two booster sessions at about three months after the tenth session

Personal construct therapy with virtual reality (PCT-VR)

Eligibility Criteria

Age18 Years - 29 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • All participants will meet diagnostic criteria for mild or moderate depressive episode according to ICD-10 (current version in the Catalan health system), diagnosed using MINI, and a score above 13 and below 29 on the BDI-II questionnaire.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University of Barcelona

Barcelona, Catalonia, 08035, Spain

Location

Associació Centre Higiene Mental Nou Barris

Barcelona, 08042, Spain

Location

Related Publications (1)

  • Montesano A, Medina JC, Paz C, Garcia-Mieres H, Nino-Robles N, Garcia-Grau E, Crespillo JC, Garcia-Gutierrez A, Alabernia-Segura M, Feixas G. Does virtual reality increase the efficacy of psychotherapy for young adults with mild-to-moderate depression? A study protocol for a multicenter randomized clinical trial. Trials. 2021 Dec 13;22(1):916. doi: 10.1186/s13063-021-05809-1.

    PMID: 34903251BACKGROUND

MeSH Terms

Conditions

Depression

Interventions

Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Guillem Feixas, Ph.D

    University of Barcelona

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
full professor

Study Record Dates

First Submitted

February 18, 2020

First Posted

March 25, 2020

Study Start

October 15, 2021

Primary Completion

July 31, 2023

Study Completion

July 31, 2024

Last Updated

December 9, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

Individual participant data for all primary and secondary outcomes, after deidentification

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available after six months of study completion
Access Criteria
Researchers who provide a methodologically sound proposal whose proposed use of the data has been approved by an independent review committee

Locations